Company Profile

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE447.05-1.15 (-0.26 % )
PREV CLOSE (Rs.) 448.20
OPEN PRICE (Rs.) 449.05
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1560
TODAY'S LOW / HIGH (Rs.)446.65 454.50
52 WK LOW / HIGH (Rs.)341.05 593.4
NSE447.45 -1.3 (-0.29 % )
PREV CLOSE(Rs.) 448.75
OPEN PRICE (Rs.) 456.85
BID PRICE (QTY) 447.45 (85 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 91182
TODAY'S LOW / HIGH(Rs.) 446.65 456.85
52 WK LOW / HIGH (Rs.)321 595

Company News

Date Heading Details
16-Jun-2020 Eris Life sciences informs about clarification on rise in volume <P align=justify>With reference to the NSE Letter no. NSE/CM/Surveillance/9623 dated 15th June, 2020, Eris Lifesciences has informed that there is no such announcement or price sensitive information, which is pending to be intimated by the Company to the stock exchanges concerning its performance/ operations. The company reiterated and clarified that all the latest relevant information about the Company, which in its opinion may have a bearing on the price/ volume behavior in the scrip has already been disclosed to the Exchanges. Further, the Company is in compliance with the SEBI (Listing Obligations and disclosures Requirements) Regulations and shall keep the stock exchanges duly informed of all the price sensitive information(s) in future as well. <BR><P align=justify>The above information is a part of company's filings submitted to BSE.
04-Jun-2020 Eris Lifesciences incorporates subsidiary company <div align="justify">Eris Lifesciences, through its wholly owned subsidiary company namely Eris Healthcare, has incorporated a subsidiary company ‘Eris Pharmaceuticals' on June 02, 2020. Eris Pharmaceuticals has been incorporated as a subsidiary of Eris Healthcare for carrying out business related to pharmaceuticals products.</div><div align="justify"><br></div><div align="justify">Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.<br></div>
11-Mar-2020 Eris Lifesciences informs about outcome of board meeting <p align="justify">Eris Lifesciences has informed that the Board of Directors of the Company at their meeting held today, March 11, 2020 duly approved the declaration of Interim Dividend of Rs 2.87 (at the rate of 287%) on each fully paid-up equity share of Re 1 for the Financial Year 2019-20. Further informed that, the Company has fixed 20th March, 2020 as the record date to determine the names of the equity shareholders, who shall be entitled to receive the payment towards interim dividend for the financial year 2019-20. The payment of the interim dividend would be made to the eligible shareholders on or before 10th April, 2020.<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
08-Feb-2020 Eris Lifesciences submits board meeting intimation <p align="justify">Eris Lifesciences has submitted the board meeting intimation.<br></p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
27-Jan-2020 Eris Lifesciences informs about updates on buyback offer <p align="justify">Axis Capital (Manager to Buyback Offer) has submitted a copy of post Buyback Public Announcement for the attention of the Equity Shareholders/ Beneficial Owners of Equity Shares of Eris Lifesciences (Target Company).<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
26-Dec-2019 Eris Lifesciences informs about trading window closure <p align="justify">Eris Lifesciences has informed that the trading window closure of the Company shall commence from 1st January, 2020 (Wednesday), till 48 hours after the declaration of financial results of the Company for the quarter ending on 31st December, 2019. Further pursuant to ‘Clause 4' of ‘Schedule B' of SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on ‘Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company', all the Designated Persons and their immediate relatives are requested not to trade in securities of the Company during the closure of the trading window. This trading window closure notice operates independently and does not intend to amend, alter, modify, curtail, or extend any other notice(s) on the closure of trading window for any other purpose, whether currently in effect or to be issued during the validity of this notice.&nbsp;<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
24-Dec-2019 Eris Lifesciences submits letter of offer <p align="justify">With reference to Proposed offer for buyback of up to 1,739,130 fully paid up equity shares of face value of Re 1 each at a price of Rs 575 per fully paid up equity share on a proportionate basis through the tender offer process of the Company, Eris Lifesciences has informed about submission of the Letter of Offer, which is dispatched to its equity shareholders as on July 15, 2019, being the record date for Buyback.&nbsp;<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
04-Dec-2019 Eris Lifesciences acquires trademark ‘Zomelis' from Novartis AG <p align="justify">Eris Lifesciences has acquired trademark ‘Zomelis' and its associated trademarks from Novartis AG, based at Basel Switzerland for Indian pharmaceuticals market with effect from December 10, 2019. The trademark has been used for marketing Vildagliptin formulations; an oral anti-diabetic drug that has been promoted in India for close to 10 years. The consideration involved in this trademark acquisition is $13 million. <br></p><p align="justify">The trademark along with its applicable associate marks presently enjoy sales on a moving annual total (MAT) basis of Rs 63.96 crore. <br></p><p align="justify">Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.<br></p>
04-Dec-2019 Eris Lifesciences informs about closure of the trading window <p align="justify">Eris Lifesciences has informed that the Trading Window of the Company shall remain closed on 4th December, 2019 and 5th December, 2019. Further pursuant to Clause 4 of Schedule B of SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company, all the Designated Persons and their immediate relatives are requested not to trade in securities of the Company during the closure of the trading window.<br></p><p align="justify">The above information is a part of company's filings submitted to BSE</p><p align="justify"><br></p>
04-Dec-2019 NITCO, Frontline Corporation and Eris Lifesciences to see some action today <p align="justify"><strong>NITCO </strong>has entered into a Non-binding term sheet to appoint Hines India Real Estate as a Development Manager for providing end to end services for office/mixed use development on 4 acre plot at Kanjurmarg, Mumbai with a development potential of around 1.3 million sq. Ft. of leasable / saleable area. </p><p align="justify"><strong>Frontline Corporation</strong> has successfully commissioned a Fuel Pump as a Franchisee of Nayra Energy (Formally Essar Oil) at National Highway No. 41 at ‘Khatian No. 2122, Plot No. 2436, 2440, 2441, 2446, Mouza Dighasipur, Taluka- Haldia, Midnapore in the state of West Bengal.<br></p><p align="justify"><strong>Eris Lifesciences</strong> has acquired trademark ‘Zomelis' and its associated trademarks from Novartis AG, based at Basel Switzerland for Indian pharmaceuticals market with effect from December 10, 2019. The trademark has been used for marketing Vildagliptin formulations; an oral anti-diabetic drug that has been promoted in India for close to 10 years. The consideration involved in this trademark acquisition is $13 million. <br></p><p align="justify"><strong>Natco Pharma</strong> has completed the investment of Rs 5 crore in OMRV Hospitals in the form of 5,00,000, 0.05% Compulsory Convertible Cumulative Preference Shares (CCCPS) under Private Placement. The company will be holding 12.81% of the shares on a fully diluted basis of Share Capital of OMRV Hospitals.<br></p><p align="justify"><strong>Indian Bank</strong> has allotted 11,72,65,954 equity shares of face value of Rs 10 each at an Issue Price of Rs 216.09 (including premium of Rs 206.09) per share aggregating to Rs 2534 crore to Government of India, Promoter of the Bank, on preferential basis.<br></p><p align="justify"><strong>Bank of Baroda</strong> has launched ‘Baroda Tabit' for digitizing the retail liability and retail asset products through tablet. The bank has been consistently working towards innovative digital offerings and ‘Current Account Opening' &amp; ‘Pre Approved Personal Loan' is a part of Digital Transformation journey.<br></p><p align="justify"><strong>LT Foods</strong> has incorporated a wholly owned subsidiary (WOS) company with a name of LT Foods Holding B.V. in Europe on December 2, 2019. The company has incorporated WOS company for rice milling, manufacturing, processing, packaging, distribution, sale, trade, import, export of food products and agricultural products.<br></p>